Phase III
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
Takeda has touted the potential of its Dengue vaccine for several years, and new long-term data reinforces the promise of the medication that could prevent the deadly mosquito-borne virus.
NGM Bio’s aldafermin failed to hit its primary endpoint in its Phase IIB trial because of that, the company decides to shift resources to other programs.
If approved, Takeda said Maribavir would become the first and only treatment indicated for CMV infection in refractory patients.
It was another busy week for clinical trial announcement. Here’s a look.
GSK said the sale of Innovia stock would help GSK invest in other “strategic priorities,” likely those aimed at plans to separate into two main offerings over the next couple of years.
Less than two weeks after Ginkgo Bioworks announced a merger with SPAC Soaring Eagle Acquisition Corp., it announced a collaboration partnership with Biogen.
Two of Merck’s Phase III pediatric trials show 15-valent pneumococcal conjugate vaccine, V114, may be safe and effective in healthy children.
Eli Lilly’s SURPASS-4 trial program shows tirzepatide, significantly reduced blood glucose levels and body weight better than insulin glargine in adult patients with type 2 diabetes.
Companies have already begun their announcements of new clinical studies for various treatment settings in preparation for ASCO 2021.
PRESS RELEASES